middle.news
How Pathkey.AI’s TrialKey Uses Drug-Level AI to Revolutionise Drug Discovery
9:29am on Thursday 18th of September, 2025 AEST
•
Healthcare
Read Story
How Pathkey.AI’s TrialKey Uses Drug-Level AI to Revolutionise Drug Discovery
9:29am on Thursday 18th of September, 2025 AEST
Key Points
TrialKey now integrates molecular structure and pharmacokinetics for improved trial success predictions
Peptide-focused study analyzed 42 trials in type 2 diabetes and obesity, identifying key success drivers
Global peptide therapeutics market projected to grow from US$117bn in 2024 to US$260bn by 2030
TrialKey evolving from clinical trial optimisation to AI-powered drug discovery and repurposing
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Pathkey.Ai (ASX:PKY)
OPEN ARTICLE